S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

Maravai LifeSciences Stock Forecast, Price & News

-0.40 (-1.56%)
(As of 01/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.56 million shs
Average Volume
1.77 million shs
Market Capitalization
$6.51 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Maravai LifeSciences logo

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$284.10 million
Cash Flow
$0.34 per share
Book Value
$0.60 per share


Net Income
$88.97 million
Pretax Margin




Free Float
Market Cap
$6.51 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End


Overall MarketRank

1.99 out of 5 stars

Medical Sector

638th out of 1,419 stocks

Pharmaceutical Preparations Industry

306th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Maravai LifeSciences (NASDAQ:MRVI) Frequently Asked Questions

Is Maravai LifeSciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Maravai LifeSciences stock.
View analyst ratings for Maravai LifeSciences
or view top-rated stocks.

Are investors shorting Maravai LifeSciences?

Maravai LifeSciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 3,890,000 shares, an increase of 25.9% from the December 15th total of 3,090,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is currently 2.7 days. Approximately 4.8% of the company's stock are sold short.
View Maravai LifeSciences' Short Interest

When is Maravai LifeSciences' next earnings date?

Maravai LifeSciences is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Maravai LifeSciences

How can I listen to Maravai LifeSciences' earnings call?

Maravai LifeSciences will be holding an earnings conference call on Wednesday, February 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "1193105".

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced its quarterly earnings data on Wednesday, November, 10th. The company reported $0.44 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.35 by $0.09. The business had revenue of $204.81 million for the quarter, compared to analyst estimates of $199.68 million. Maravai LifeSciences had a net margin of 22.69% and a trailing twelve-month return on equity of 109.36%.
View Maravai LifeSciences' earnings history

What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY 2022 earnings guidance on Wednesday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $840 million-$880 million, compared to the consensus revenue estimate of $789.84 million.

What price target have analysts set for MRVI?

4 brokers have issued twelve-month price targets for Maravai LifeSciences' shares. Their forecasts range from $54.00 to $62.00. On average, they expect Maravai LifeSciences' stock price to reach $58.25 in the next year. This suggests a possible upside of 130.7% from the stock's current price.
View analysts' price targets for Maravai LifeSciences
or view top-rated stocks among Wall Street analysts.

Who are Maravai LifeSciences' key executives?

Maravai LifeSciences' management team includes the following people:
  • Mr. Carl W. Hull, Co-Founder, Chairman & CEO (Age 62, Pay $1.25M)
  • Mr. Brian Neel, Chief Operating Officer of Nucleic Acid Production (Age 45, Pay $987.1k)
  • Mr. Kevin M. Herde, VP & CFO (Age 49)
  • Ms. Debra Hart, Sr. Director of Investor Relations
  • Mr. Kurt Oreshack, Gen. Counsel & Sec. (Age 40)
  • Ms. Christine Dolan, Chief Operating Officer of Biologics Safety Testing (Age 53)
  • Ms. Lisa V. Sellers, Chief Operating Officer of Protein Detection (Age 49)

When did Maravai LifeSciences IPO?

(MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

What is Maravai LifeSciences' stock symbol?

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.07%), WCM Investment Management LLC (0.04%), GAM Holding AG (0.02%), Tributary Capital Management LLC (0.01%), Bessemer Group Inc. (0.01%) and Carnegie Capital Asset Management LLC (0.01%).

Which institutional investors are selling Maravai LifeSciences stock?

MRVI stock was sold by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Tributary Capital Management LLC, and Cutler Group LP.

Which institutional investors are buying Maravai LifeSciences stock?

MRVI stock was bought by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, Strs Ohio, Carnegie Capital Asset Management LLC, Bessemer Group Inc., CAPROCK Group Inc., New York State Teachers Retirement System, GAM Holding AG, and Regentatlantic Capital LLC.

How do I buy shares of Maravai LifeSciences?

Shares of MRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Maravai LifeSciences' stock price today?

One share of MRVI stock can currently be purchased for approximately $25.25.

How much money does Maravai LifeSciences make?

Maravai LifeSciences has a market capitalization of $6.51 billion and generates $284.10 million in revenue each year. The company earns $88.97 million in net income (profit) each year or $1.04 on an earnings per share basis.

How many employees does Maravai LifeSciences have?

Maravai LifeSciences employs 3 workers across the globe.

What is Maravai LifeSciences' official website?

The official website for Maravai LifeSciences is www.maravai.com.

Where are Maravai LifeSciences' headquarters?

Maravai LifeSciences is headquartered at 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Maravai LifeSciences?

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The company can be reached via phone at 858-546-0004 or via email at [email protected].

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.